Vertex Secures Reimbursement for CASGEVY Therapy in Germany for Sickle Cell and Beta Thalassemia
Vertex Pharmaceuticals has announced a reimbursement agreement with Germany's GKV-Spitzenverband for its gene-edited therapy, CASGEVY, targeting sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This agreement ensures access to the therapy for eligible patients aged 12 and older in Germany. CASGEVY, a CRISPR/Cas9 gene-edited cell therapy, modifies a patient's hematopoietic stem cells to produce high levels of fetal hemoglobin, reducing or eliminating vaso-occlusive crises in SCD and transfusion needs in TDT. The therapy is already reimbursed in several countries, including the U.S., and represents a significant advancement for patients with these life-shortening genetic diseases. 
